Corvus Pharmaceuticals (CRVS) Income from Non-Controlling Interests (2015 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Income from Non-Controlling Interests came in at -$334000.0 in Q1 2026, down 1352.17% year-on-year from $26673.6 in Q1 2025, and down 1251.72% quarter-over-quarter from $29000.0 in Q3 2025.
Corvus Pharmaceuticals (CRVS) Income from Non-Controlling Interests (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Income from Non-Controlling Interests history runs 12 years deep, the most recent figure standing at -$334000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 1352.17% year-over-year to -$334000.0 in Q1 2026; TTM through Mar 2026 was -$347000.0, a 391.6% decrease from a year earlier, with the FY2023 full-year figure at $66000.0, up 237.5% from the prior year.
- Income from Non-Controlling Interests retreated to -$334000.0 in Q1 2026 per CRVS's latest filing, from $29000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $152000.0 in Q3 2024 and bottomed at -$334000.0 in Q1 2026.
- The 5-year median for Income from Non-Controlling Interests is $5000.0 (2022), against an average of -$12466.7.
- Across the five-year window, Income from Non-Controlling Interests sank 1500.0% in 2022 and surged 2940.0% in 2024, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $29000.0 in 2022, then slipped by 27.59% to $21000.0 in 2023, then jumped by 623.81% to $152000.0 in 2024, then tumbled by 80.92% to $29000.0 in 2025, then plunged by 1251.72% to -$334000.0 in 2026.
- Per Business Quant, the three latest CRVS Income from Non-Controlling Interests figures stand at -$334000.0 (Q1 2026), $29000.0 (Q3 2025), and -$19000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | -334,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -334,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -23,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | 41,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | -54,000.00 |
| Mar 31, 2022 | -28,000.00 |
| Dec 31, 2021 | -3,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | -8,000.00 |